{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T14:42:52Z","timestamp":1785422572447,"version":"3.56.0"},"reference-count":53,"publisher":"AOSIS","issue":"1","license":[{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:p>Long-term antidepressant pharmacotherapy is frequently continued beyond guideline-recommended durations. This occurs particularly among women, despite limited evidence of ongoing benefit for many people treated for mild-to-moderate depression and an increasing burden of adverse effects over time. In randomised trials, average symptom improvement over placebo is small (approximately 2 points on the 52-point Hamilton Depression Rating Scale), with an estimated number needed to treat of about 7\u201310 for a clinically meaningful benefit, underscoring the importance of planning for discontinuation once treatment is initiated. Antidepressant withdrawal is common yet under-recognised: at least half of people experience withdrawal symptoms when stopping, with risk and severity increasing with higher doses, longer duration of use and prior withdrawal experiences. This Therapeutic Letter outlines a practical, patient-centred approach to deprescribing that tailors tapering to individual risk, uses clinical response to guide the pace of reduction and emphasises careful differentiation of withdrawal symptoms from relapse. To minimise harms, abrupt discontinuation should be avoided; higher-risk patients may require very gradual tapering over months or years, often using hyperbolic dose reductions enabled by liquid formulations or dissolving tablets, with close follow-up every 2\u20134 weeks and the option to pause or reverse tapering if symptoms emerge. The guidance also highlights strategies for challenging presentations, including withdrawal-associated akathisia and protracted withdrawal, alongside patient education, shared decision-making and informed consent to support safer discontinuation and improved outcomes.<\/jats:p>","DOI":"10.4102\/phcfm.v18i1.5431","type":"journal-article","created":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T12:22:13Z","timestamp":1773663733000},"update-policy":"https:\/\/doi.org\/10.4102\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Stopping antidepressants safely"],"prefix":"10.4102","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1318-2029","authenticated-orcid":false,"given":"Mark","family":"Horowitz","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/023e5m798","id-type":"ROR","asserted-by":"publisher"}],"name":"North East London NHS Foundation Trust"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2850-4206","authenticated-orcid":false,"given":"Thomas L.","family":"Perry","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03rmrcq20","id-type":"ROR","asserted-by":"publisher"}],"name":"University of British Columbia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2580","published-online":{"date-parts":[[2026,3,31]]},"reference":[{"key":"ref0","unstructured":"Horowitz M, Taylor D. The Maudsley deprescribing guidelines in psychiatry: Antidepressants, benzodiazepines, gabapentinoids and z-drugs [homepage on the Internet]. 2024 [cited 2025 Jul 17]. Available from: https:\/\/scholar.google.com\/citations?view_op=view_citation&hl=en&citation_for_view=sEcbBuUAAAAJ:abG-DnoFyZgC"},{"key":"ref1","unstructured":"Cruickshank G, Macgillivray S, Bruce D, et al. Cross-sectional survey of patients in receipt of long-term repeat prescriptions for antidepressant drugs in primary care. Ment Health Fam Med. 2008;5(2):105\u2013109."},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Piek E, Kollen BJ, Van der Meer K, et al. Maintenance use of antidepressants in Dutch general practice: Non-guideline concordant. PLoS One. 2014;9(5):e97463. https:\/\/doi.org\/10.1371\/journal.pone.0097463","DOI":"10.1371\/journal.pone.0097463"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Ambresin G, Palmer V, Densley K, et al. What factors influence long-term antidepressant use in primary care? Findings from the Australian diamond cohort study. J Affect Disord. 2015;176:125\u2013132. https:\/\/doi.org\/10.1016\/j.jad.2015.01.055","DOI":"10.1016\/j.jad.2015.01.055"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Eveleigh R, Muskens E, Lucassen P, et al. Withdrawal of unnecessary antidepressant medication: A randomised controlled trial in primary care. BJGP Open. 2018;1(4):bjgpopen17X101265. https:\/\/doi.org\/10.3399\/bjgpopen17X101265","DOI":"10.3399\/bjgpopen17X101265"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Davidson SK, Romaniuk H, Chondros P, et al. Antidepressant treatment for primary care patients with depressive symptoms: Data from the diamond longitudinal cohort study. Aust N Z J Psychiatry. 2020;54(4):367\u2013381. https:\/\/doi.org\/10.1177\/0004867419898761","DOI":"10.1177\/0004867419898761"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Poon E, Donald M, Van Driel M, et al. Patterns and duration of antidepressant use in Australian women: Findings from the Australian longitudinal study on women\u2019s health. Asia Pac J Public Health. 2025;37(2\u20133):272\u2013280. https:\/\/doi.org\/10.1177\/10105395251321316","DOI":"10.1177\/10105395251321316"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Mojtabai R, Olfson M. National trends in long-term use of antidepressant medications: Results from the U.S. National Health and Nutrition Examination Survey. J Clin Psychiatry. 2014;75(2):169\u2013177. https:\/\/doi.org\/10.4088\/JCP.13m08443","DOI":"10.4088\/JCP.13m08443"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Wallis KA, King A, Moncrieff J. Antidepressant prescribing in Australian primary care: Time to reevaluate. Med J Austr. 2025;222(9):430\u2013432. https:\/\/doi.org\/10.5694\/mja2.52645","DOI":"10.5694\/mja2.52645"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Hengartner MP. Is there a genuine placebo effect in acute depression treatments? A reassessment of regression to the mean and spontaneous remission. BMJ Evid Based Med. 2020;25(2):46\u201348. https:\/\/doi.org\/10.1136\/bmjebm-2019-111161","DOI":"10.1136\/bmjebm-2019-111161"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Munkholm K, Paludan-Muller AS, Boesen K. Considering the methodological limitations in the evidence base of antidepressants for depression: A reanalysis of a network meta-analysis. BMJ Open. 2019;9(6):e024886. https:\/\/doi.org\/10.1136\/bmjopen-2018-024886","DOI":"10.1136\/bmjopen-2018-024886"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Arroll B, Elley CR, Fishman T, et al. Antidepressants versus placebo for depression in primary care. Cochr Database Syst Rev. 2009;2009(3):CD007954. https:\/\/doi.org\/10.1002\/14651858.CD007954","DOI":"10.1002\/14651858.CD007954"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Kinrys G, Gold AK, Pisano VD, et al. Tachyphylaxis in major depressive disorder: A review of the current state of research. J Affect Disord. 2019;245:488\u2013497. https:\/\/doi.org\/10.1016\/j.jad.2018.10.357","DOI":"10.1016\/j.jad.2018.10.357"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Serretti A, Chiesa A. Treatment-emergent sexual dysfunction related to antidepressants: A meta-analysis. J Clin Psychopharmacol. 2009;29(3):259\u2013266. https:\/\/doi.org\/10.1097\/JCP.0b013e3181a5233f","DOI":"10.1097\/JCP.0b013e3181a5233f"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Hindmarch I, Alford C, Barwell F, Kerr JS. Measuring the side effects of psychotropics: The behavioural toxicity of antidepressants. J Psychopharmacol. 1992;6(2):198\u2013203. https:\/\/doi.org\/10.1177\/026988119200600","DOI":"10.1177\/026988119200600212"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Goodwin GM, Price J, De Bodinat C, Laredo J. Emotional blunting with antidepressant treatments: A survey among depressed patients. J Affect Disord. 2017;221:31\u201335. https:\/\/doi.org\/10.1016\/j.jad.2017.05.048","DOI":"10.1016\/j.jad.2017.05.048"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Langley C, Armand S, Luo Q, et al. Chronic escitalopram in healthy volunteers has specific effects on reinforcement sensitivity: A double-blind, placebo-controlled semi-randomised study. Neuropsychopharmacology. 2023;48(4):664\u2013670. https:\/\/doi.org\/10.1038\/s41386-022-01523-x","DOI":"10.1038\/s41386-022-01523-x"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Dragioti E, Solmi M, Favaro A, et al. Association of antidepressant use with adverse health outcomes: A systematic umbrella review. JAMA Psychiatry. 2019;76(12):1241\u20131255. https:\/\/doi.org\/10.1001\/jamapsychiatry.2019.2859. Anonymous. Data Error in Table: JAMA Psychiatry. 2021;78(5):569. https:\/\/doi.org\/10.1001\/jamapsychiatry.2021.0314","DOI":"10.1001\/jamapsychiatry.2019.2859"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Coupland C, Dhiman P, Morriss R, et al. Antidepressant use and risk of adverse outcomes in older people: Population based cohort study. BMJ. 2011;343:d4551. https:\/\/doi.org\/10.1136\/bmj.d4551","DOI":"10.1136\/bmj.d4551"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Gafoor R, Booth HP, Gulliford MC. Antidepressant utilisation and incidence of weight gain during 10 years\u2019 follow-up: Population based cohort study. BMJ. 2018;361:k1951 https:\/\/doi.org\/10.1136\/bmj.k1951","DOI":"10.1136\/bmj.k1951"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Coupland CAC, Hill T, Dening T, et al. Anticholinergic drug exposure and the risk of dementia: A nested case-control study. JAMA Intern Med. 2019;179:1084\u20131093. https:\/\/doi.org\/10.1001\/jamainternmed.2019.0677","DOI":"10.1001\/jamainternmed.2019.0677"},{"key":"ref21","unstructured":"Prescrire. SSRI antidepressants and venlafaxine: Increased risk of injuries. Prescrire Int. 2025;34(269):105\u2013106."},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Bansal N, Hudda M, Payne RA, et al. Antidepressant use and risk of adverse outcomes: Population-based cohort study. BJPsych Open. 2022;8(5):e164. https:\/\/doi.org\/10.1192\/bjo.2022.563","DOI":"10.1192\/bjo.2022.563"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Horowitz MA, Buckman JEJ, Saunders R, et al. Antidepressants withdrawal effects and duration of use: A survey of patients enrolled in primary care psychotherapy services. Psychiatry Res. 2025;350:116497. https:\/\/doi.org\/10.1016\/j.psychres.2025.116497","DOI":"10.1016\/j.psychres.2025.116497"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Van Leeuwen E, Driel ML, Horowitz MA, et al. Approaches for discontinuation versus continuation of long-term antidepressant use for depressive and anxiety disorders in adults. Cochr Database Syst Rev. 2021;4:CD013495. https:\/\/doi.org\/10.1002\/14651858.CD013495.pub2","DOI":"10.1002\/14651858.CD013495.pub2"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Wallis KA, Donald M, Horowitz M, et al. RELEASE (REdressing Long-tErm Antidepressant uSE): Protocol for a 3-arm pragmatic cluster randomised controlled trial effectiveness-implementation hybrid type-1 in general practice. Trials. 2023;24(1):615. https:\/\/doi.org\/10.1186\/s13063-023-07646-w","DOI":"10.1186\/s13063-023-07646-w"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Coe A, Gunn J, Kaylor-Hughes C. General practice patients\u2019 experiences and perceptions of the WiserAD structured web-based support tool for antidepressant deprescribing: Protocol for a mixed methods case study with realist evaluation. JMIR Res Protocols. 2022;11(12):e42526. https:\/\/doi.org\/10.2196\/42526;","DOI":"10.2196\/42526"},{"key":"ref27","unstructured":"Melbourne Medical School WiserAD: A randomized trial of a structured online intervention to promote and support antidepressant de-prescribing in primary care [homepage on the Internet]. [cited 2025 Jul 09]. Available from: https:\/\/medicine.unimelb.edu.au\/research-groups\/general-practice-and-primary-care-research\/primary-care-mental-health\/wiserad-a-randomised-trial-of-a-structured-online-intervention-to-promote-and-support-antidepressant-de-prescribing-in-primary-care"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"Van Os J, Groot PC. Outcomes of hyperbolic tapering of antidepressants. Ther Adv Psychopharmacol. 2023;13:20451253231171520. https:\/\/doi.org\/10.1177\/20451253231171518","DOI":"10.1177\/20451253231171518"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"Horowitz MA, Taylor D. Tapering of SSRI treatment to mitigate withdrawal symptoms. Lancet Psychiatry. 2019;6(6):538\u2013546. https:\/\/doi.org\/10.1016\/S2215-0366(19)30032-X","DOI":"10.1016\/S2215-0366(19)30032-X"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"G\u00f8tzsche PC, Demasi M. Interventions to help patients withdraw from depression drugs: A systematic review. Int J Risk Saf Med. 2024;35(2):103\u2013116. https:\/\/doi.org\/10.3233\/JRS-230011","DOI":"10.3233\/JRS-230011"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"Lewis G, Marston L, Duffy L, et al. Maintenance or discontinuation of antidepressants in primary care. N Engl J Med. 2021;385(14):1257\u20131267. https:\/\/doi.org\/10.1056\/NEJMoa2106356","DOI":"10.1056\/NEJMoa2106356"},{"key":"ref32","unstructured":"Gardner D. Understanding antidepressant medications part 2: When and how to safely stop them [homepage on the Internet]. [cited 2025 Jul 09]. Available from: https:\/\/static1.squarespace.com\/static\/5836f01fe6f2e1fa62c11f08\/t\/679d15c7d5442f445e3ee980\/1738347977229\/article-antidepressants_part2_EN-2025-01-28.pdf"},{"key":"ref33","unstructured":"Lilly USA LLC. Fluoxetine (Prozac) U.S. label 2016 approved by the FDA [homepage on the Internet]. Reference ID: 4036401. [cited 2025 Jul 09]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/018936s108lbl.pdf"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"Horowitz MA, Framer A, Hengartner MP, et al. Estimating risk of antidepressant withdrawal from a review of published data. CNS Drugs. 2023;37(2):143\u2013157. https:\/\/doi.org\/10.1007\/s40263-022-00960-y","DOI":"10.1007\/s40263-022-00960-y"},{"key":"ref35","doi-asserted-by":"crossref","unstructured":"Kendrick T, Stuart B, Bowers H, et al. Internet and telephone support for discontinuing long-term antidepressants: The REDUCE cluster randomized trial. JAMA Netw Open. 2024;7(6):e2418383. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.18383","DOI":"10.1001\/jamanetworkopen.2024.18383"},{"key":"ref36","unstructured":"UK NICE. Depression in adults: Treatment and management [homepage on the Internet]. NICE; 2022 [cited 2025 Jul 09]. Available from: https:\/\/www.nice.org.uk\/guidance\/ng222"},{"key":"ref37","unstructured":"Royal College of Psychiatrists. Stopping antidepressants [homepage on the Internet]. [cited 2025 Jul 09]. Available from: https:\/\/www.rcpsych.ac.uk\/docs\/default-source\/mental-health\/treatments-and-wellbeing\/print-outs\/stopping-antidepressants-information-resource-print-version-18-03-24.pdf?sfvrsn=76e4b9a8_3"},{"key":"ref38","doi-asserted-by":"crossref","unstructured":"Read J, Moncrieff J, Horowitz MA. Designing withdrawal support services for antidepressant users: Patients\u2019 views on existing services and what they really need. J Psychiatr Res. 2023;161:298\u2013306. https:\/\/doi.org\/10.1016\/j.jpsychires.2023.03.013","DOI":"10.1016\/j.jpsychires.2023.03.013"},{"key":"ref39","doi-asserted-by":"crossref","unstructured":"Fava GA, Cosci F. Understanding and managing withdrawal syndromes after discontinuation of antidepressant drugs. J Clin Psychiatry. 2019;80:6. https:\/\/doi.org\/10.4088\/JCP.19com12794","DOI":"10.4088\/JCP.19com12794"},{"key":"ref40","doi-asserted-by":"crossref","unstructured":"Quilichini JB, Revet A, Garcia P, et al. Comparative effects of 15 antidepressants on the risk of withdrawal syndrome: A real-world study using the WHO pharmacovigilance database. J Affect Disord. 2022;297:189\u2013193. https:\/\/doi.org\/10.1016\/j.jad.2021.10.041","DOI":"10.1016\/j.jad.2021.10.041"},{"key":"ref41","doi-asserted-by":"crossref","unstructured":"Gastaldon C, Schoretsanitis G, Arzenton E, et al. Withdrawal syndrome following discontinuation of 28 antidepressants: Pharmacovigilance analysis of 31,688 reports from the WHO Spontaneous Reporting Database. Drug Saf. 2022;45(12):1539\u20131549. https:\/\/doi.org\/10.1007\/s40264-022-01246-4","DOI":"10.1007\/s40264-022-01246-4"},{"key":"ref42","doi-asserted-by":"crossref","unstructured":"Lam RW, Kennedy SH, Adams C, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2023 Update on Clinical Guidelines for Management of Major Depressive Disorder in Adults: R\u00e9seau canadien pour les traitements de l\u2019humeur et de l\u2019anxi\u00e9t\u00e9 (CANMAT) 2023: Mise \u00e0 jour des lignes directrices cliniques pour la prise en charge du trouble d\u00e9pressif majeur chez les adultes. Can J Psychiatry. 2024;69(9):641\u2013687. https:\/\/doi.org\/10.1177\/07067437241245384","DOI":"10.1177\/07067437241245384"},{"key":"ref43","doi-asserted-by":"crossref","unstructured":"Henssler J, Schmidt Y, Schmidt U, et al. Incidence of antidepressant discontinuation symptoms: A systematic review and meta-analysis. Lancet Psychiatry. 2024;11(7):526\u2013535. https:\/\/doi.org\/10.1016\/S2215-0366(24)00133-0","DOI":"10.1016\/S2215-0366(24)00133-0"},{"key":"ref44","unstructured":"The University of Queensland. RELEASE: REdressing Long-tErm Antidepressant uSE [homepage on the Internet]. [cited 2025 Jul 09]. Available from: https:\/\/releaseuq.notion.site\/RELEASE-REdressing-Long-tErm-Antidepressant-uSE-c81416ad6f7d41a1bbd274bb248a22c2"},{"key":"ref45","unstructured":"Odan Laboratories Ltd. Odan-Fluoxetine product monograph [homepage on the Internet]. 2016 [cited 2025 Jul 09]. Available from: https:\/\/pdf.hres.ca\/dpd_pm\/00037306.PDF"},{"key":"ref46","unstructured":"Apotex Inc. Apo-Fluoxetine product monograph [homepage on the Internet]. 2022 [cited 2025 Jul 09]. Available from: https:\/\/pdf.hres.ca\/dpd_pm\/00066452.PDF"},{"key":"ref47","unstructured":"Bostwick J, Demehri A. Pills to powder: An updated clinician\u2019s reference for crushable psychotropics [homepage on the Internet]. 2017 [cited 2025 Jul 09]. Available from: https:\/\/www.mdedge.com\/psychiatry\/article\/130305\/bipolar-disorder\/pills-powder-updated-clinicians-reference-crushable"},{"key":"ref48","unstructured":"Anonymous. A range of selective serotonin reuptake inhibitor (SSRI) formulations are suitable for adults with swallowing difficulties [homepage on the Internet]. SPS \u2013 Specialist Pharmacy Service; 2024 [cited 2025 Jul 09]. Available from: https:\/\/www.sps.nhs.uk\/articles\/selective-serotonin-reuptake-inhibitor-ssri-formulations-suggested-for-adults-with-swallowing-difficulties\/"},{"key":"ref49","doi-asserted-by":"crossref","unstructured":"Framer A. What I have learnt from helping thousands of people taper off psychotropic medications. Therapeutic Adv Psychopharmacol. 2021;11:2045125321991274. https:\/\/doi.org\/10.1177\/2045125321991274","DOI":"10.1177\/2045125321991274"},{"key":"ref50","unstructured":"Akathisia Alliance for education and research. Akathisia: General information [homepage on the Internet]. [cited 2025 Jul 09]. Available from: https:\/\/akathisiaalliance.org\/about-akathisia\/"},{"key":"ref51","doi-asserted-by":"crossref","unstructured":"Hengartner MP, Schulthess L, Sorensen A, Framer A. Protracted withdrawal syndrome after stopping antidepressants: A descriptive quantitative analysis of consumer narratives from a large internet forum. Therapeutic Adv Psychopharmacol. 2020;10:2045125320980573. https:\/\/doi.org\/10.1177\/2045125320980573","DOI":"10.1177\/2045125320980573"},{"key":"ref52","unstructured":"Therapeutics Initiative. How to stop antidepressants; Ther Lett [serial online]. 2025 [cited 2026 Jan 29];157. Available from: https:\/\/www.ti.ubc.ca\/letter157"}],"container-title":["African Journal of Primary Health Care &amp; Family Medicine"],"original-title":[],"deposited":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T12:22:20Z","timestamp":1773663740000},"score":1,"resource":{"primary":{"URL":"https:\/\/phcfm.org\/index.php\/phcfm\/article\/view\/5431"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,31]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1,1]]}},"URL":"https:\/\/doi.org\/10.4102\/phcfm.v18i1.5431","relation":{},"ISSN":["2071-2928","2071-2936"],"issn-type":[{"value":"2071-2928","type":"print"},{"value":"2071-2936","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,31]]},"article-number":"a5431"}}